To study this, we employed CRISPR-Cas9 gene editing [29] to manipulate calpain-1/2 expression in the highly metastatic human MDA-MB-231 triple-negative breast cancer cell line. The gene discussed is CAPN1; the disease is triple-negative breast carcinoma.